Gut Microbiome Intervention (EXL01) With Nivolumab and FOLFOX in First-line Treatment for PD-L1 CPS ≥5 Metastatic Gastric Cancer: GERCOR Phase II Study (BIG)
Conditions: Gastric Cancer Interventions: Drug: Nivolumab; Drug: FOLFOX regimen; Biological: EXL01 Sponsors: GERCOR - Multidisciplinary Oncology Cooperative Group Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Gastric (Stomach) Cancer | Gastroenterology | Research | Study